Accessing the HER2-Targeting Potential in Areas of Vast Unmet Clinical Need: Pre Conference Workshop Day - Tuesday June, 14
Understanding Pathology & Potential for Exploiting HER2-Targeting in Gastrointestinal Cancers
10am - 12pm
With the surge and huge progress in HER2 agents in gastric cancer, HER2 positive colorectal cancer alongside a few other GI cancers have been left relatively untapped. We will delve into the updates for gastric & GEJ, and the clinical challenges of targeting colorectal & other attractive GI cancers and how to understand the knowledge of this disease to apply your HER2 therapy to the patients who have limited treatment options.
• Understanding disease progression and current screening programs
• How do you select for CRC? How many patients are eligible for trials? What is the access to clinical trials? What does it look like in the US? What are people willing to travel for?
• Understand how the GI clinical landscape is evolving and where anti-HER2 agents could fit in
• Combination and treatment considerations for colorectal cancers from a clinician’s standpoint
Harvard Medical School
MGH Cancer Center's Global Cancer Care Program
Samuel J. Klempner
MGH Cancer Center, Harvard Medical School
GI Oncology, Instructor in Medicine
Division of Gastrointestinal Oncology, Dana-Farber Cancer Institute
Understanding Pathology & Potential for Exploiting HER2-Targeting in CNS Metastasis
1:00 - 3:00pm
With the FDA’s push to treat the whole patient and not merely one stage of the disease, it is impossible to ignore the correlation between the diseases we are treating with HER2-targeted therapies and the strong link to CNS metastasis
• Movement for small molecules including TKIs and some ADCs now to act on the CNS and work, but what do we need to know about the disease, be that CNS metastatic disease or glioblastoma, to help us improve drug design, development, trial design and treatment regimes for patients?
• Understand the pathology of CNS disease, why they are so difficult to treat and how HER2 plays a role in this
• The promise for HER2 targeting and how to optimize your drug with CNS metastasis in mind, from the eyes of disease specialists
• Why are the agents having an effect on CNS metastasis working?
• Toxicity profiles role in the CNS
• Molecular profiling to be done? Which patients are benefiting? Other biomarkers of interest?
• How to integrate brain metastasis in therapeutic regime: physiopathology and selection
Co-Director & Assistant Professor -
Breast Medical Oncology
Associate Professor, Medicine, Harvard Medical School,
Active Staff, Adult Oncology, Dana-Farber Cancer Institute
& Clinical Director, Breast Oncology Center, Medical Oncology, Dana-Farber Cancer Institute